



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

9 September 2019

Imagion commences Non Deal Roadshow in Australia

MELBOURNE — Imagion Biosystems Limited (ASX: IBX) (the **Company**), a company dedicated to improving healthcare through the earlier detection of cancer is pleased to share the updated investor presentation.

Chief Executive Officer Robert (Bob) Proulx is conducting an investor roadshow in Sydney, Melbourne and Perth from Monday 9 - Friday 13 September, 2019.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Buchan
ImagionBiosystems@we-buchan.com
+61-3-9866-4722



MagSense™ Technology

Early Detection of Cancer Through Targeted Imaging

ASX:IBX

www.imagionbiosystems.com

DISCLAIMER



*This investor presentation (**Presentation**) has been prepared by Imagion Biosystems Limited (**Imagion** or the **Company**). This presentation does not constitute or form part of, and should not be construed as, an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Imagion or any member of its group nor should it or any part of it form the basis of, or be relied on in connection with, any contract to purchase or subscribe for any securities of Imagion or any member of its group, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever.*

This presentation is not a Prospectus and contains summary information about Imagion and its activities, which is current as at the date of this presentation. The information included in this presentation is of a general nature and does not purport to be complete nor does it contain all the information which a prospective investor should consider when making an investment decision. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation including but not limited to the assumptions, uncertainties and contingencies which may affect future operations of Imagion and the impact that different future outcomes may have on Imagion. This presentation has been prepared without taking account of any person's investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, make their own assessment of the information and seek legal, financial, accounting and taxation advice appropriate to their jurisdiction in relation to the information and any action taken on the basis of the information. Imagion is an early stage medical technology company and has so far has not conducted research in human subjects.

The information included in this presentation has been provided to you solely for your information and background and is subject to updating, completion, revision and amendment and such information may change materially. Unless required by applicable law or regulation, no person (including Imagion) is under any obligation to update or keep current the information contained in this presentation and any opinions expressed in relation thereto are subject to change without notice. No representation or warranty, express or implied, is made as to the fairness, currency, accuracy, reasonableness or completeness of the information contained herein. Neither Imagion nor any other person (including its shareholders, directors, officers and employees) accepts any liability and Imagion, its shareholders, its related bodies corporate and their respective directors, officers and employees, to the maximum extent permitted by law, expressly disclaim all liabilities for any loss howsoever arising, directly or indirectly, from this presentation or its contents.

This presentation includes forward-looking statements that reflect Imagion's intentions, beliefs or current expectations concerning, among other things, Imagion's results of operations, financial condition, performance, prospects, growth, strategies and the industry in which Imagion operates. These forward-looking statements are subject to risks, uncertainties and assumptions and other factors, many of which are beyond the control of Imagion. Imagion cautions you that forward-looking statements are not guarantees of future performance and that its actual results of operations, financial condition, performance, prospects, growth or opportunities and the development of the industry in which Imagion operates may differ materially from those made in or suggested by the forward-looking statements contained in this presentation. In addition, Imagion does not guarantee any particular rate of return or the performance of Imagion nor does it guarantee the repayment or maintenance of capital or any particular tax treatment. Investors should note that past performance may not be indicative of results or developments in future periods and cannot be relied upon as an indicator of (and provides no guidance as to) Imagion's future performance. Imagion, its related bodies corporate and each of their respective directors, officers and employees and advisers expressly disclaim any obligation or undertaking to review, update or release any update of or revisions to any forward-looking statements in this presentation or any change in Imagion's expectations or any change in events, conditions or circumstances on which these forward-looking statements are based, except as required by applicable law or regulation.

This presentation and any materials distributed in connection with this presentation are not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.

The distribution of this presentation in certain jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions.



1 in 3 People are affected by Cancer

“Early detection of many diseases, particularly cancers, is key to successful treatment.”

“Despite technical advances in many areas of diagnostic radiology, the detection and imaging of human cancer remains poor. “

Chemical Reviews 2015 Nanoparticles in Medicine Vol 115

Journal of Clinical Oncology, 2008 New Technologies for Human Cancer Imaging Vol 26 No 24

MEDICAL IMAGING BREAKTHROUGH

MagSense™ Technology will transform cancer diagnosis



- Non-invasive, non-radioactive – a safe and non-surgical solution to detect cancer
- Uses bio-safe tiny nanoparticles to “tag” cancer cells
- FDA Breakthrough Designation supports transformative status
- First indication – metastatic breast cancer - provides shortest path to commercialization
- Platform technology for many types of cancer as well as other diseases, e.g. infection and cardiovascular
- Patent issued in most major global markets
- Highly de-risked: technical feasibility and safety profile vetted
- First-in-human studies a catalyst event



EXPERIENCED TEAM

Commercially focused team with deep industry & clinical experience



ROBERT PROULX
CHAIRMAN & CEO

- Operationally oriented executive
- 25 years in life science & medical devices
- Product development & commercialization



MICHAEL HARSH
NON EXEC DIRECTOR

- Former CTO of GE Healthcare
- 35 years in medical imaging product development



DAVID LUDVIGSON
NON EXEC DIRECTOR

- 35 years in pharma, medical device
- Corporate strategy, M&A, & financing



BRONWYN LE GRICE
NON EXEC DIRECTOR

- 15 years in Australian commercial healthcare & technology markets



BRIAN CONN
CFO

- CFO for early & growth stage biotech
- 25 years raising both public & private capital & M&A



MARIE ZHANG PHD
VP R&D

- 20 years in drug development
- Leadership in early stage and startup founder



MARK VAN ASTEN
NON EXEC DIRECTOR

- Strong track record in diagnostics & healthcare
- 25 commercializing diagnostic products



JOVANKA NAUMOSKA
NON EXEC DIR & COSEC

- Australian attorney with expertise in regulatory compliance, governance & risk management

World class scientific collaborations & partnerships:



JOHN HAZLE PHD
CHAIR - SAB

- Board certified in medical physics
- 30 years in pre-clinical & clinical imaging research
- Chairs Cancer Research at UT Graduate School of Biomedical Sciences



CAPITAL STRUCTURE



Ordinary shares on issue	323.71M
--------------------------	---------

Share price (5 Sept 2019)	0.041
---------------------------	-------

Average daily volume	4.77M
----------------------	-------

Market capitalization	12.62M
-----------------------	--------

Net cash (30 June 2019)	\$1.1M (+ further \$2M via R&D tax credit in July)
-------------------------	---

Major Shareholders (as of 19th Aug 2019)

Manhattan Scientifics Inc	19.8%
Mr Kemper Shaw	9.82%
Drake Special Situations LLC	7.72%
William Taylor Nominees	6.70%
Board & Management	0.41%



CLEAR UNMET MEDICAL NEED

50 years since last new imaging technology was introduced



Current technologies:



- Identify a “region of interest”
- Expose patients to radiation
- Require invasive biopsies to confirm
- Result in unnecessary biopsies



HOW IT WORKS




Bio-safe magnetic nanoparticles are attracted to the tumor and detected



- Nanoparticles, specific for the cancer, bind to tumor cells
- Nanoparticles demagnetize or “relax” after exposure to a low magnetic field
- Nanoparticles attached to cancer cells “relax” more slowly than particles in circulation
- Ultra-sensitive detectors locate the presence of attached nanoparticles

STRATEGIC PLAN

Path to future products & value



DESIGNATED BREAKTHROUGH DEVICE



First indication – metastatic breast cancer – provides fastest path to commercialisation

IMPROVES PATIENT OUTCOMES

- Staging of metastatic HER2+ breast cancer eliminates lymphadenectomy for 50% of patients
- Detection of primary tumor would eliminate uncertainties from mammograms

LOW-RISK SAFETY PROFILE

- Uses known materials – iron oxide used as contrast agent
- Safety profile has been affirmed as low risk by FDA
- Toxicology study successfully completed

STREAMLINED REGULATORY PATHWAY

- Not regulated as a drug
- Small scale clinical studies


The MagSense™ system and test has been designated FDA Breakthrough Device Status reserved for products that provide for more effective treatment or diagnosis.

“The goal of the Breakthrough Devices Program is to provide... timely access to these medical devices by speeding up their development, assessment, and review.”

TRANSFORMATIVE, NOT DISRUPTIVE




Improved outcomes, within existing clinical workflow



MILESTONES AND VALUATION DRIVERS



*Indicative development timeline and key inflection points**













* This development timeline is indicative only, and subject to change.

MAJOR PLAYERS ARE INVESTING



Creating markets creates multi-billion dollar deals

Deal Size	US\$370M	Undisclosed	US\$85M	US\$716M	US\$1.7B	Undisclosed
Year	2019	2019	2019	2017	2017	2017
Acquirer						
Target						
Technology	Mobile CT scanner and robotics tech	Cloud-enabled enterprise imaging platform	Medical imaging / ultrasound system	Flourescence imaging technology	Medical aesthetics	Image analysis software


STRONG R&D PIPELINE



Product Applications Under Development

MagSense
Pipeline

Nanoparticle
Pipeline



* in collaboration with 3rd party

INVESTMENT HIGHLIGHTS



LARGE OPPORTUNITY

\$100B cancer diagnostic market

Growing 7% annually

Medical imaging commands largest share

Under-addressed need for early diagnosis



UNIQUE TECHNOLOGY

New form of medical imaging

Molecularly specific & non-invasive

More sensitive than current methods

Protected by eight patents



COMMERCIAL STRATEGY

\$2B initial market focus

Applies to many types of cancer

Printer-ink revenue model

Potential for therapeutics & research markets



HIGHLY DE-RISKED

Technical feasibility demonstrated

Safety profile of technology vetted

Management & Board with track record bringing products to market



IMAGION BIOSYSTEMS

www.imagionbiosystems.com